JPM 2022: Pfizer CEO eyes 50% boost to Paxlovid production—and capacity expansions, toonews2022-01-10T22:23:07+00:00January 10th, 2022|Fierce Pharma|
JPM 2022: Bristol Myers plots 3 blockbuster launches to counter Revlimid’s patent cliffnews2022-01-10T19:27:19+00:00January 10th, 2022|Fierce Pharma|
JPM 2022: Amid underwhelming Aduhelm launch, Biogen supports limited Medicare coverage, exec saysnews2022-01-10T16:27:30+00:00January 10th, 2022|Fierce Pharma|
JPM 2022: New Johnson & Johnson CEO Duato points out 5 pipeline meds that can generate $5B+news2022-01-10T16:25:38+00:00January 10th, 2022|Fierce Pharma|
JPM 2022: New Johnson & Johnson CEO Duato points out 5 pipeline meds that can generate $5B-plusnews2022-01-10T16:25:38+00:00January 10th, 2022|Fierce Pharma|
2seventy brings in Genevant delivery tech for Novo Nordisk in vivo gene editing projectnews2022-01-10T16:19:39+00:00January 10th, 2022|Fierce Pharma|
J&J, following in Sanofi’s footsteps, tasks i2o with oral delivery of large moleculesnews2022-01-10T16:17:09+00:00January 10th, 2022|Fierce Pharma|
JPM 2022: Vertex’s Trikafta holds the line as company lays groundwork for gene editing launchnews2022-01-10T15:54:34+00:00January 10th, 2022|Fierce Pharma|
Merck, eyes on Roche’s immunotherapy first, returns perplexing Keytruda post-surgery lung cancer datanews2022-01-10T14:43:57+00:00January 10th, 2022|Fierce Pharma|
Recipharm unloads a pair of plants in separate deals as part of its streamlining, growth strategynews2022-01-10T13:46:35+00:00January 10th, 2022|Fierce Pharma|
